A Mechanism of Action of Metformin in the Brain: Prevention of Methylglyoxal-Induced Glutamatergic Impairment in Acute Hippocampal Slices

• DOI: 10.1007/s12035-023-03774-1
• Publication Date: 2023-11-18T20:02:26Z
• Authors: Adriana Fernanda ...; Fernanda Fróes; Marina Seady; Fernanda Hansen; Rodrigo Ligabue-B...; Carlos-Alberto Go...; Diogo O. Souza
• Keywords: Male; Neuroprotective Agents; Astrocytes; Amino Acid Transport System X-AG; Receptor for Advanced Glycation End Products; Interleukin-1beta; Animals; Glutamic Acid; Rats, Wistar; Pyruvaldehyde; Hippocampus; Metformin; 3. Good health

Metformin, a biguanide compound (N-1,1-dimethylbiguanide), is widely prescribed for diabetes mellitus type 2 (T2D) treatment. It also presents a plethora of properties, such as anti-oxidant, anti-inflammatory, anti-apoptosis, anti-tumorigenic, and anti-AGE formation activity. However, the precise mechanism of action of metformin in the central nervous system (CNS) needs to be clarified. Herein, we investigated the neuroprotective role of metformin in acute hippocampal slices exposed to methylglyoxal (MG), a highly reactive dicarbonyl compound and a key molecule in T2D developmental pathophysiology. Metformin protected acute hippocampal slices from MG-induced glutamatergic neurotoxicity and neuroinflammation by reducing IL-1β synthesis and secretion and RAGE protein expression. The drug also improved astrocyte function, particularly with regard to the glutamatergic system, increasing glutamate uptake. Moreover, we observed a direct effect of metformin on glutamate transporters, where the compound prevented glycation, by facilitating enzymatic phosphorylation close to Lys residues, suggesting a new neuroprotective role of metformin via PKC ζ in preventing dysfunction in glutamatergic system induced by MG.